Virtu Financial LLC Invests $5.08 Million in argenex SE $ARGX

Virtu Financial LLC bought a new stake in argenex SE (NASDAQ:ARGX) in the 4th quarter, Holdings Channel reports. The fund bought 6,041 shares of the company’s stock, valued at approximately $5,080,000.

A number of other large investors have also added to or reduced their stakes in ARGX. AQR Capital Management LLC increased its stake in argenex by 32.1% during the 1st quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock worth $297,000 after buying an additional 122 shares during the period. NewEdge Advisors LLC boosted its position in argenex by 5,962.5% in the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock valued at $862,000 after buying an additional 1,431 shares during the last quarter. Focus Partners Wealth grew its stake in shares of argenex by 22.3% during the first quarter. Focus Partners Wealth now owns 400 shares of the company’s stock valued at $237,000 after acquiring an additional 73 shares in the last quarter. Geneos Wealth Management Inc. grew its stake in shares of argenex by 550.0% during the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after acquiring an additional 99 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its position in shares of argenex by 60.2% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock worth $73,000 after acquiring an additional 50 shares during the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. HC Wainwright boosted their price target on argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Wedbush restated an “outperform” rating and set a $1,000.00 price objective on shares of argenex in a research note on Thursday, June 11th. Deutsche Bank Aktiengesellschaft upgraded argenex from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. Oppenheimer dropped their price objective on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a report on Thursday, April 2nd. Finally, Royal Bank Of Canada cut their target price on argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a research report on Friday, February 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,019.50.

argenex Price Performance

Shares of ARGX stock opened at $877.72 on Friday. The firm has a fifty day moving average of $822.61 and a two-hundred day moving average of $810.57. The firm has a market cap of $54.59 billion, a P/E ratio of 39.08, a P/E/G ratio of 1.36 and a beta of 0.47. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62.

argenex (NASDAQ:ARGX) last issued its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. The business had revenue of $1.31 billion for the quarter. On average, sell-side analysts expect that argenex SE will post 26.19 EPS for the current year.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.